Matthew Austin

Dr. Matthew Austin


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Journal of Brown Hospital Medicine
Verified
Journal Article
Open access
PDF file
PMPrashanth Moku
Prashanth Moku
BBBrianna Bakow
Brianna Bakow
AMArun Muthiah
Arun Muthiah
MBMark Birkenbach
Mark Birkenbach
MAMatthew Austin
Matthew Austin
Immune checkpoint inhibitors (ICIs) have revolutionized the field of medical oncology. This class of medications block molecules responsible for inhibiting the immune response to cancer, allowing for immune system activation, tumor recognition and destruction of cancer cells. A unique side-effect of these drugs involves the immune-mediated destruction of healthy tissue, known as immune-related adverse events (irAEs). One example is the autoimmune destruction of renal tissue associated with development of acute interstitial nephritis (AIN). Here, we present a case of a patient with metastatic bladder cancer treated with an ICI who developed AIN that was refractory to glucocorticoid therapy and salvaged by mycophenolate mofetil. The case illustrates the unique mechanism by which toxicity can occur, demonstrates the concept of delayed irAEs, and highlights the prolonged, durable responses patients with cancer can have to immunotherapy, even after treatment is discontinued.

23 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MAMatthew Austin
Matthew Austin
Harriet KlugerHarriet Kluger
Harriet Kluger
In recent years, it has become clear that the immune system plays a critical role in rejecting malignant cells